EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer

Chie Kudo-Saito, Hiroshi Imazeki, Kengo Nagashima, Hirokazu Shoji, Kai Tsugaru, Naoki Takahashi, Takeshi Kawakami, Yusuke Amanuma, Takeru Wakatsuki, Fumio Nagashima, Yukiya Narita, Yoshiyuki Yamamoto und 3 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04239-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Chie Kudo-Saito und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan. ckudo@ncc.go.jp. Hauptthemen laut MEDLINE: Follistatin-Related Proteins, Stomach Neoplasms, Biomarkers, Tumor, Nivolumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ono Pharmaceutical, Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follistatin-like 1 (FSTL1) has been demonstrated to be a key molecule in cancer intractability associated with immune exhaustion and dysfunction, and increased expression of FSTL1 and its receptor DIP2A in tumor tissues has also been reported as a significant poor prognostic factor in various types of cancer, including gastric cancer (GC). However, the relationship between FSTL1/DIP2A levels, especially those in the peripheral circulation, and clinical outcomes in anti-PD1/PDL1 therapy remains to be elucidated in clinical practice. We collected peripheral blood collected from patients with advanced GC before and after nivolumab monotherapy, and analyzed for FSTL1 by ELISA, and for DIP2A+ cells by flow cytometry, followed by statistical analysis of association with patient prognosis. High FSTL1 levels at baseline were significantly associated with shorter progression-free survival (PFS) and overall survival (OS). Patients with high levels of DIP2A+ subsets in CD11b+ myeloid cells, CD3+ T cells, and CD56+ NK cells both before and after treatment showed significantly shorter PFS and OS as compared to patients with low levels. Combination of low baseline levels of both FSTL1 and DIP2A+ cells identified patients with long-term survival, known as durable responders. These data suggest that high baseline levels of both FSTL1 and DIP2A+ cells in peripheral blood are significant poor prognostic factors for nivolumab therapy for advanced GC. Targeting the FSTL1-DIP2A axis may be a promising strategy to improve clinical outcomes in GC as a biomarker to predict anti-PD1/PDL1 therapeutic efficacy more accurately.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Follistatin-Related ProteinsStomach NeoplasmsBiomarkers, TumorNivolumabProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedPrognosisAgedAdult

Stichwörter der Autor:innen

BiomarkerDIP2AFSTL1Gastric cancerImmune checkpointPD1

Substanzen

Follistatin-Related ProteinsFSTL1 protein, humanBiomarkers, TumorNivolumabProgrammed Cell Death 1 ReceptorPDCD1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan. ckudo@ncc.go.jp.
  • Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.
  • Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Keio University Hospital, Tokyo, Japan.
  • Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.

Förderung

  • Ono Pharmaceutical
  • Bristol-Myers Squibb

Zitieren

APA

Kudo-Saito, C., Imazeki, H., Nagashima, K., Shoji, H., Tsugaru, K., Takahashi, N., Kawakami, T., Amanuma, Y., Wakatsuki, T., Nagashima, F., Narita, Y., Yamamoto, Y., Kizawa, R., Muro, K., & Boku, N. (2025). The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04239-1

Vancouver

Kudo-Saito C, Imazeki H, Nagashima K, Shoji H, Tsugaru K, Takahashi N, et al. The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04239-1

BibTeX
@article{KudoSaito2025,
  author = {Kudo-Saito, Chie and Imazeki, Hiroshi and Nagashima, Kengo and Shoji, Hirokazu and Tsugaru, Kai and Takahashi, Naoki and Kawakami, Takeshi and Amanuma, Yusuke and Wakatsuki, Takeru and Nagashima, Fumio and Narita, Yukiya and Yamamoto, Yoshiyuki and Kizawa, Rika and Muro, Kei and Boku, Narikazu},
  title = {The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04239-1}
}
Kostenlos starten →